OBJECTIVE: We aimed to investigate survival outcomes and survival-related prognostic factors in gastric cancer patientswho were followed-up or received adjuvant therapy in our center.METHODS: Patients with gastric cancer treated between 2005 and 2016 were evaluated retrospectively. We included 345non-metastatic (stage I-III) gastric cancer patients in the study. The clinical, demographic, histologic data of the patients andtreatment characteristics were obtained from the patient’s files.RESULTS: While 50 patients were stage I, 94 patients were stage II, 201 patients were stage III. While 221 patients (64%)presenting with serosal or adjacent visceral organ invasion or with involved lymph nodes were treated with adjuvant chemoradiotherapy, 124 patients presenting with early-stage disease were followed after surgery. Median follow up time was 34months (4–156 months). While the median overall survival (OS) was 51 months, median disease-free survival (DFS) was 35months. Overall survival and disease-free survival rates for 1st, 3rd and 5th years were 85%, 55%, 45% and 72%, 49%, 38%,respectively. According to univariate analysis, tumor size, T stage (p<0.001), N stage (p<0.001), TNM stage (p<0.001), grade(p<0.001) and presence of lymphovascular invasion (p=0.005) were determined as prognostic factors that affect overallsurvival significantly. According to the multivariate analysis, only T and N stage (p<0.001) were determined as independentprognostic factors for overall survival.CONCLUSION: Many different prognostic factors have been defined for gastric cancer. In concordance with the literature,we found T and N stages as prognostic factors in univariate and multivariate analysis.